Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) researched for its ability to stimulate the pituitary gland to release endogenous growth hormone. It occupies an unusual position in peptide research: it is the rare GH-axis compound backed by large Phase 3 clinical trials — and the only one with an FDA-approved drug form, Egrifta, approved in 2010 for HIV-associated lipodystrophy.
That approved status makes a critical distinction necessary from the outset: Egrifta is a prescription pharmaceutical. Vonox Labs sells research-use-only tesamorelin material — not Egrifta.
Ver materiales de investigación: Tienda VONOX Labs
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.
What Is Tesamorelin?
Tesamorelin is a chain of 44 amino acids modeled on human growth hormone-releasing hormone (which is itself 44 amino acids long), with a chemical modification at the N-terminus — a trans-3-hexenoyl group — added to improve stability. It was developed under the code name TH9507 by Theratechnologies.
It belongs to the GHRH analog family — compounds that mimic the hypothalamic hormone commanding the pituitary to release growth hormone. This places it in the same mechanistic family as CJC-1295 (another synthetic GHRH analog), but in a different family from ghrelin-mimetic secretagogues such as ipamorelin, GHRP-2, and GHRP-6, which stimulate GH through the ghrelin receptor (GHS-R1a) instead.
Research has investigated tesamorelin for its relationship with pituitary GH release, IGF-1 elevation, visceral adipose tissue, lipid metabolism, liver fat, and body composition in HIV-associated lipodystrophy.
How Does Tesamorelin Work?
Tesamorelin has been studied as an agonist of the GHRH receptor on pituitary somatotrophs — the cells that synthesize and secrete growth hormone. Researchers have investigated its relationship with:
- GHRH-receptor agonism — binding the same receptor as endogenous GHRH, tesamorelin stimulates the pituitary to produce and release its own growth hormone, rather than supplying GH directly
- Preserved GH pulsatility — because it works through the body’s own regulatory pathway, GH release retains its natural episodic pattern with increased pulse amplitude rather than continuous output
- IGF-1 elevation — GH released in response to tesamorelin drives hepatic IGF-1 production; IGF-1 levels were a key measured endpoint across the clinical trials
- Visceral adipose effects — the trials focused on tesamorelin’s studied effects on visceral abdominal fat, the deep fat depot associated with metabolic risk
- Lipid metabolism — trial programs measured tesamorelin’s relationship with triglycerides, total cholesterol, and related lipid markers
Key Takeaway: Tesamorelin is particularly interesting to researchers because it amplifies the body’s own GH axis through the natural GHRH pathway — and because, unlike nearly every other research peptide, its effects were measured in large, well-controlled human trials rather than only in animal models.
Potential Benefits of Tesamorelin
Visceral Fat Reduction (Phase 3 Trials)
The core of the tesamorelin evidence base is the reduction of visceral adipose tissue (VAT) in HIV-infected patients with abdominal fat accumulation (lipodystrophy).
In a 26-week randomized, double-blind, placebo-controlled Phase 3 trial of 412 patients, tesamorelin (2 mg daily) reduced visceral fat by approximately 15% relative to placebo, while increasing IGF-1 levels (Falutz et al., New England Journal of Medicine, 2007). The trial also reported improvements in triglycerides and total cholesterol, with lean body mass generally preserved — a notable finding, since the fat loss was not accompanied by the muscle loss seen with caloric restriction.
A pooled analysis of two Phase 3 trials with safety-extension data reported that VAT reduction was sustained with continued treatment and that IGF-1 elevation persisted, contributing longer-term safety observations to the profile (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010).
Liver Fat Research
A separate randomized clinical trial investigated tesamorelin’s effects on hepatic (liver) fat alongside visceral fat in HIV-infected patients with abdominal fat accumulation, reporting reductions in both visceral and liver fat versus placebo (Stanley et al., JAMA, 2014). This extended the compound’s studied metabolic profile beyond the abdominal compartment to ectopic fat in the liver.
IGF-1 and GH-Axis Research
Across the trial program, tesamorelin consistently elevated IGF-1 levels, confirming engagement of the GH axis in humans at the studied doses — one reason tesamorelin is referenced in GH-axis research more broadly: it is one of the few GHRH-pathway compounds with documented, dose-characterized GH-axis activation in large human cohorts. These trial findings were measured in a specific patient population and should not be stretched into broader body-composition claims.
Tesamorelin vs. Other GH-Axis Peptides
Tesamorelin has a different research profile from peptides such as BPC-157 and TB-500, which are studied for tissue repair rather than endocrine signaling.
CJC-1295 is tesamorelin’s closest research counterpart: both are synthetic GHRH analogs acting through the GHRH receptor. The key differences are structural and regulatory — CJC-1295 carries modifications designed to extend half-life, it has no FDA-approved form, and its evidence base is preclinical and early-phase rather than Phase 3.
Ipamorelin stimulates GH through the entirely separate ghrelin receptor (GHS-R1a) pathway. Researchers study tesamorelin and ipamorelin as probes of the two natural GH-release pathways, and the growth hormone secretagogues guide covers how GHRH-pathway and ghrelin-pathway stimulation interact.
Tesamorelin’s research is more closely associated with:
GHRH Receptor Agonism → Endogenous Pulsatile GH → IGF-1 Elevation → Visceral & Liver Fat Reduction (in studied populations)
What sets tesamorelin apart is the weight of its human evidence: large randomized trials in a defined clinical population, an FDA-approved drug form, and a safety database far larger than that of any other GH-axis research peptide.
Regulatory Status
Tesamorelin’s regulatory position is worth stating plainly — and precisely, because it is genuinely unusual:
- Tesamorelin IS FDA approved — as the drug product Egrifta (tesamorelin for injection), approved in 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Egrifta is a prescription pharmaceutical manufactured to drug standards.
- Vonox Labs does not sell Egrifta. Vonox Labs sells research-use-only tesamorelin material — not manufactured as a pharmaceutical, not subject to drug approval, and not for human or veterinary use. The approved drug and the research material must not be conflated: FDA approval of Egrifta does not apply to any research chemical.
- Outside the approved indication and population, tesamorelin’s studied effects (including any body-composition findings) are research observations, not established medical uses.
What Does the Research Say?
The tesamorelin literature provides an unusually solid basis for research into GHRH-pathway GH stimulation — large randomized trials, a defined patient population, replicated VAT findings, and an approved drug with a real safety database. The evidence limits, however, should be understood clearly:
First, the trial population was specific: HIV-infected patients with abdominal fat accumulation (lipodystrophy). Tesamorelin has not been studied in randomized trials in the general population for body composition, and the findings should not be generalized beyond the studied context.
Second, the studied outcomes were fat-depot measurements and biomarkers (VAT, liver fat, IGF-1, lipids) — not long-term clinical outcomes such as cardiovascular events or mortality.
Third, glucose metabolism was a monitored safety area in the program: the clinical literature includes observations of glycemic changes, and the approved drug’s labeling carries warnings related to glucose intolerance. This is a researched caution, not a footnote.
Fourth, FDA approval covers one indication in one population. Approval of Egrifta is not evidence for any other use of tesamorelin, and it says nothing about research-use material sold outside the pharmaceutical system.
An approved drug with real trial data is the strongest evidence position any research peptide can hold — and it is still bounded by the population studied and the indication approved.
Frequently Asked Questions
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), developed as TH9507. It stimulates the pituitary gland to release endogenous growth hormone through the GHRH receptor.
How does tesamorelin work?
It binds GHRH receptors on pituitary somatotrophs, stimulating the body’s own pulsatile growth hormone release. The resulting GH elevation drives hepatic IGF-1 production. Researchers have studied its effects on visceral fat, liver fat, and lipid metabolism.
What did the clinical trials show?
In Phase 3 trials of HIV-infected patients with abdominal fat accumulation, 26 weeks of tesamorelin reduced visceral adipose tissue by approximately 15% versus placebo, increased IGF-1, and improved triglyceride and cholesterol markers, with lean mass generally preserved. A separate trial reported reductions in liver fat.
Is tesamorelin FDA approved?
Yes — as the prescription drug Egrifta (tesamorelin for injection), approved in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Vonox Labs sells research-use-only tesamorelin material, not Egrifta; the two must not be confused.
How is tesamorelin different from CJC-1295?
Both are GHRH analogs acting through the GHRH receptor, but tesamorelin has an FDA-approved drug form and a large Phase 3 trial program in HIV-associated lipodystrophy, while CJC-1295 is research-only with a long-acting structural modification and a preclinical/early-phase evidence base.
The Bottom Line
Tesamorelin holds the strongest human evidence position of any GH-axis research peptide — large Phase 3 trials demonstrating visceral fat reduction and IGF-1 elevation, a replicated safety database, and an FDA-approved drug form (Egrifta, 2010) for HIV-associated lipodystrophy.
That strength comes with boundaries: the evidence belongs to a specific patient population, the approved indication is narrow, glycemic effects are a researched caution, and the approved pharmaceutical is a different thing from research-use material. Read within those boundaries, tesamorelin is the reference compound for GHRH-pathway research in humans.
Explore Tesamorelin
Learn more about Tesamorelin and explore our research-focused Tesamorelin peptide at Vonox Labs: Tesamorelin
Research. Test. Learn.
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.
Scientific References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/ (Phase 3: 26 weeks of tesamorelin reduced visceral fat ~15% vs placebo and raised IGF-1 in 412 HIV patients.)
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. https://pubmed.ncbi.nlm.nih.gov/20554713/ (Pooled Phase 3 analysis: sustained VAT reduction with continued treatment; extension safety data.)
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/ (Randomized trial: tesamorelin reduced visceral and liver fat vs placebo.)
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. https://pubmed.ncbi.nlm.nih.gov/21668043/ (Review of tesamorelin’s trial program and approved use as Egrifta.)
Leave a Reply